EMA: AZD1222 causes serious rare ADEs
In a new statement, the EU regulatory authority EMA postulates that AstraZeneca’s vaccine causes serious deep vein thrombosis.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2213 entries already.
Entries by Thomas Gabrielczyk
Trading medical cannabis in Europe
The regulatory situation regarding the trade of medicinal cannabis currently varies enormously from country to country within the European Union. Unfortunately, there is still no full regulatory harmonization on a European level.
Targeting SARS-CoV-2 differently
German structural biologists have identified seven compounds that neutralise SARS-CoV-2 by targeting Mpro, the virus’ main protease.
miRNAs unmask vulnerability in breast cancer stem cells
Researchers in Italy have identified a pair of microRNA molecules, miR-146A and miR-, help maintain a population of breast cancer stem cells
Advancing protein production with Pichia pastoris
Effective bioprocess development starts with the targeted and time-saving generation of high-productivity strains already considering economic target values and regulatory requirements. The UNLOCK PICHIA technology platform comprises a large number of versatile expression tools for the generation and identification of effective industrial protein production strains without compromising development timelines.
Janssen to pledge COVID-19 vaccine to African Union
Johnson & Johnson subsidiary Janssen Pharmaceutica NV has confirmed to deliver 220 million doses of its COVID-19 vaccine to the African Vaccine Acquisition Trust (AVAT).
Bispecific IgG switch off SARS-CoV-2 escape variants
A bispecific antibody designed by a Swiss-Czech research team suppressed viral escape of SARS-CoV-2 variants in animals.
European Biotechnology Guide 2021
The 11th edition of the European Biotechnology Science & Industry Guide once more offers an interesting cross-section of the European biotech scene.
Step Pharma SAS raises €35m in Series B
Kurma Partners-founded Step Pharma has baged €35m in a Series B financing to advance its blood cancer lead STP938.
AAV vectors from a CDMO that cares about SMEs
The future of AAV vector-based therapies holds great promise if manufacturers can cope with the demand. While in-house manufacturing may be an option for some companies, partnering with a CDMO can be the best choice for others. Teaming up with a One-Stop-Shop CDMO can make it easier to achieve the project goals. There are many reasons for this.